A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03

Woo Jin Hyung¹ · Han-Kwang Yang² · Sang-Uk Han³ · Young-Jun Lee⁴ · Joong-Min Park⁵ · Jin Jo Kim⁶ · Oh Kyung Kwon⁷ · Seong Ho Kong² · Hyoung-Il Kim¹ · Hyuk-Joon Lee² · Wook Kim⁸ · Seung Wan Ryu⁹ · Sung-Ho Jin¹⁰ · Sung Jin Oh¹¹ · Keun Won Ryu¹² · Min-Chan Kim¹³ · Hye-Seong Ahn¹⁴ · Young Kyu Park¹⁵ · Young-Ho Kim¹⁶ · Sun-Hwi Hwang¹⁷ · Jong Won Kim⁵ · Gyu Seok Cho¹⁸

Received: 5 March 2018 / Accepted: 5 August 2018 / Published online: 20 August 2018
© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Abstract

Background With improved short-term surgical outcomes, laparoscopic distal gastrectomy has rapidly gained popularity. However, the safety and feasibility of laparoscopic total gastrectomy (LTG) has not yet been proven due to the difficulty of the technique. This single-arm prospective multi-center study was conducted to evaluate the use of LTG for clinical stage I gastric cancer.

Methods Between October 2012 and January 2014, 170 patients with pathologically proven, clinical stage I gastric adenocarcinoma located at the proximal stomach were enrolled. Twenty-two experienced surgeons from 19 institutions participated in this clinical trial. The primary end point was the incidence of postoperative morbidity and mortality at postoperative 30 days. The severity of postoperative complications was categorized according to Clavien–Dindo classification, and the incidence of postoperative morbidity and mortality was compared with that in a historical control.

Results Of the enrolled patients, 160 met criteria for inclusion in the full analysis set. Postoperative morbidity and mortality rates reached 20.6% (33/160) and 0.6% (1/160), respectively. Fifteen patients (9.4%) had grade III or higher complications, and three reoperations (1.9%) were performed. The incidence of morbidity after LTG in this trial did not significantly differ from that reported in a previous study for open total gastrectomy (18%).

Conclusions LTG performed by experienced surgeons showed acceptable postoperative morbidity and mortality for patients with clinical stage I gastric cancer.

Keywords Gastric cancer · Laparoscopy · Total gastrectomy

Introduction

Laparoscopic distal subtotal gastrectomy for gastric cancer has been widely adopted in recent years, particularly in East Asia [1]. As the number of laparoscopic distal gastrectomies performed has increased, several large-scale randomized clinical trials of laparoscopic applications for gastric cancer have been conducted [2–4]. According to these trials, laparoscopic distal gastrectomy is technically feasible and safe,

and compared to open distal gastrectomy, is less likely to involve complications [5, 6].

Unlike subtotal gastrectomy, laparoscopic total gastrectomy for proximal gastric cancer has been slowly accepted, primarily because of technical difficulties with performing the surgery. During the procedure, lymph node dissection around the distal pancreas and splenic hilum poses a tremendous challenge due to complicated vascular structures and a greater risk of pancreatic injury. Moreover, esophagojejunal anastomosis, which has not yet been standardized, is also considered to be one of the difficult parts. Because of these shortcomings, most surgeons are reluctant to perform laparoscopic total gastrectomy for proximal gastric cancer.

Verifying the safety of laparoscopic total gastrectomy will help widen the application thereof. Although several studies

✉ Gyu Seok Cho
gschogs@schmc.ac.kr

Extended author information available on the last page of the article

have assessed the safety of laparoscopic total gastrectomy [7–12], these have mostly been single-center retrospective studies of a small sample size. To yield robust evidence of the safety and feasibility of laparoscopic total gastrectomy, the Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) group proposed a prospective multi-center trial of laparoscopic total gastrectomy for clinical stage I gastric cancer to determine the safety and feasibility of laparoscopic total gastrectomy (KLASS-03 trial). In doing so, we aimed to assess types of postoperative complications and the incidence of 30-day postoperative morbidity and mortality following laparoscopic total gastrectomy. We also sought to compare operative outcomes after laparoscopic total gastrectomy with those reported in a previous study for open total gastrectomy [13].

Methods

Patients

We conducted a single-arm prospective multi-center study from October 2012 to January 2014. Inclusion criteria were as follows: patients of ages from 20 to 80 years, the presence of pathologically proven gastric adenocarcinoma, diagnosis of clinical stage IA (cT1N0M0) or IB (cT1N1M0 and cT2N0M0) disease based on the 7th UICC/AJCC TNM staging system, no indication for endoscopic submucosal dissection, Eastern Cooperative Oncology Group (ECOG) performance status < 1, and an American Society of Anesthesiology (ASA) score < III. We excluded those who had synchronous or metachronous malignant tumors in other organs within the past 5 years, a history of upper abdominal laparotomy, a history of any gastric surgery, and/or lymph node enlargement in the splenic hilum (lymph node station number 10) on a computed tomography scan.

When patients met the selection criteria, they were informed of the study objectives, and informed consent was obtained prior to registry with the data center. A serial number was assigned by the data center according to the order of registration, and all surgeries were to be performed within 30 days. The institutional review boards of all participating centers approved this study. This study was registered at ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01584336).

Surgeons

Twenty-two surgeons from 19 centers participated in this clinical trial. All participating institutions perform more than 80 gastrectomies per year for gastric cancer. All participating surgeons had experience of both laparoscopic and open gastrectomy procedures more than 50, respectively. During

the preparation period for KLASS-03 trial, we held several investigator meetings in which all participating surgeons reviewed their operation videos altogether and made an agreement on esophagojejunostomy techniques among surgeons. All surgeons already had performed enough number of laparoscopic subtotal gastrectomy or total gastrectomy for stage I gastric cancer. All participating surgeons are specialized surgeons for gastric cancer surgery and working at the high-volume center.

Operative interventions

Lymph node dissection was performed in accordance with the following principles: D1 + lymph node dissection to be performed for clinical stage IA disease and D2 lymph node dissection (8a, 9, 11p, 11d, and 12a lymph node stations), except lymph node station number 10, to be performed for clinical stage IB disease. D2 lymphadenectomy including the lymph nodes in the splenic hilum (lymph node station number 10) was performed in cases with suspicious serosal involvement or metastasis to the splenic hilar lymph node in the laparoscopic view.

Reconstruction was achieved according to the clinical practice of each institution. Either extracorporeal or intracorporeal anastomosis was allowed for reconstruction. Any type of stapled anastomosis using either a circular or linear staplers was allowed for the esophagojejunostomy. A drainage tube was inserted into the gastric bed along the upper border of the pancreas. We measured size of mini-laparotomy for anastomosis and specimen delivery as the length of the skin incision.

Postoperative management

For postoperative management, a standardized clinical pathway was applied, including dietary build-up and blood and radiography examinations. If a patient tolerated three meals of a soft diet without gastrointestinal symptoms and if their vital signs had stabilized, they were advised to be discharged from the hospital. Adjuvant chemotherapy was recommended when pathological results confirmed stage II or more advanced cancer.

Outcomes

We assessed patient disease history, ECOG performance status, and ASA score preoperatively. We also collected data on total operation time, anastomosis time, type of esophagojejunal reconstruction, location and length of a mini-laparotomy, extent of lymph node dissection, estimated blood loss volume, and intraoperative complications as operative findings. The anastomosis time was defined as the time for all anastomosis-related procedures, including esophagojejunostomy

and jejunojejunostomy, jejunal stump closure, and mesenteric defect repair. Estimated blood loss was measured by checking suction volumes and gauze weights during surgery. Intraoperative complications were classified as massive bleeding, vascular injury, other organ injuries around the stomach, anastomosis failure, hypercarbia, and any added techniques or delayed incidents, including additional treatments performed during surgery.

Postoperative complications that occurred within 30 days after surgery were assessed according to Clavien–Dindo classification [14], and readmission was recorded along with the reason thereof. Postoperative mortality was defined as any death within 30 days after surgery and death related to complications regardless of timing. Before beginning this study, we consulted with the Italian Gastric Cancer Study Group, which previously conducted a randomized control trial study for open total gastrectomy, to establish criteria for and types of complications used in their study, with which we sought to compare [13]. Complications after surgery were classified largely into systemic and local complications

(Table 1). We also assessed long-term mortality rates of laparoscopic total gastrectomy to provide baseline data for a phase-III study through which to prove the oncological safety thereof.

Sample size

This study was designed to verify the safety of laparoscopic total gastrectomy by proving the non-inferiority thereof in relation to the incidence of complications after an open conventional approach based on a historical control. For the past 10 years, we found only one multi-center prospective study reporting a complication rate of 18% (12 of 66 patients) following open total gastrectomy [13]. Thus, we used the 18% complication rate as the comparative historical control. To calculate the limitation of non-inferiority, we collected 16 studies on complications after open total gastrectomy published in English for the past 10 years and conducted a meta-analysis [8, 9, 13, 15–27]. As a result, the 95% confidence interval of the upper limit was determined to be 26.6%, and

Table 1 Definition of complications

Systemic complications	
Pulmonary	Additional treatments were required, such as therapeutic antibiotics, percutaneous drainage, or mechanical ventilation due to atelectasis, pleural effusion, empyema, pneumonia, and pneumothorax accompanied by symptoms, such as febricity and dyspnea
Urinary	Additional treatments were required, such as catheter re-insertion due to dysuria and urinary retention
Cardiac	Treatments were required due to symptoms of heart failure after surgery, myocardial ischemia, or infarction
Systemic infection	Symptoms of fever due to infection, increased number of neutrophils, and pathogen cultures from a blood culture examination
Local complications	
Wound	Extended hospitalization due to surgical wound infection and additional treatment other than simple disinfection was required
Ascites	Additional treatments were required due to retention of intraperitoneal fluid or abdominal distension after an abdominal ultrasound examination or tomography
Postoperative ileus	Fasting more than 7 days after surgery due to enteroplegia or drainage that occurred through the nasogastric tube
Abdominal abscess	Intra-abdominal abscesses or infected body fluids were found after an abdominal ultrasound examination or tomography such that the additional use of antibiotics or additional treatment was required, such as drainage or reoperation
Pancreatic leakage	Amylase level in peritoneal fluid discharged through the drainage tube was > 1,000 IU, protein $\geq$ 3.0 g/dL; amylase and protein levels in peritoneal fluid discharged through the drainage tube were routinely measured on postoperative day 4
Acute pancreatitis	Symptoms, such as abdominal pain or fever after surgery, accompanied by abdominal CT results or blood amylase levels greater than three times the normal level
Intra-abdominal bleeding	Bleeding through the drainage tube installed inside the abdominal cavity and additional treatments required, such as blood transfusion, reoperation, and embolization due to bleeding, confirmed through imaging tests accompanied by a decrease in serum hemoglobin
Anastomotic bleeding	Additional treatments required, such as transfusion, endoscopic surgery, and reoperation, due to a decrease in plasma hemoglobin level caused by anastomotic bleeding confirmed through endoscopy
Anastomotic stenosis	Fasting or drainage, endoscopic intervention, and reoperation required due to food discharge difficulties below the anastomotic site after surgery
Anastomotic leakage	Leakage at the anastomotic site confirmed clinically and radiologically after surgery
Duodenal stump leakage	Duodenal suture leakage confirmed clinically and radiologically
Miscellaneous	Additional treatment required due to patient complaints about symptoms other than those listed above

the threshold value was 8%. Thus, the sample size for the present trial was estimated at 168 patients, with a 15% drop-out rate, a significance level of 0.05, and a statistical power of 0.8.

Statistics

A full analysis set (FAS) was included to assess the primary outcome in the current trial. The FAS was designated as patients who completed their assigned treatment, excluding those who declined to participate in the study after giving consent and being registered and those who did not undergo total gastrectomy. Only the major and most severe Clavien–Dindo classification grade for each patient was used in determining complication rates. All *p* values < 0.05 were considered significant. All statistical analyses were conducted using SPSS software, ver. 18.0 (SPSS Inc., Chicago, IL, USA).

Results

Patient characteristics (Table 2)

In total, 170 patients were registered from October 2012 to January 2014. Of these, 160 met the FAS criteria. As shown in Fig. 1, the 10 patients were excluded for the following reasons: one enrollment violation, one withdrawal from the study after giving signed informed consent, and eight other types of gastrectomy, including one laparoscopic proximal gastrectomy and seven laparoscopic distal gastrectomies.

More than twice as many male patients than female patients were enrolled, and 50.2% of all patients had comorbidities, including 15.6% who had more than two associated diseases. Eleven patients (6.9%) were treated by endoscopic submucosal dissection initially and underwent subsequent laparoscopic total gastrectomy due to tumor invasion to submucosal layers or resection margins. All patients were stage I clinically; none had lesions extending to the esophagus; and seven patients (4.4%) had lesions involving the gastroesophageal junction. Final pathological examination revealed stage I disease in 88.1% of patients and stage II disease in the remaining 11.9% (19 cases).

Operative outcomes (Table 3)

The mean operation time was 226.7 min, and the mean anastomosis time was 50.7 min (22.4% of the total operation time). Esophagojejunostomy was performed extracorporeally through a mini-laparotomy in 45 patients (28.1%). For extracorporeal anastomosis, the mini-laparotomy incision was made in the epigastrium in 39 patients, the left upper abdomen in five, and the umbilicus in one. Meanwhile, for

Table 2 Patient clinical characteristics

Variable	N = 160	(%)
Age (years)	59.2 ± 10.2	
Gender		
Male	115	71.9
Female	45	28.1
Body mass index (kg/m ²)	24.0 ± 2.9	
Comorbidities		
None	78	48.8
Single	57	35.6
Multiple	25	15.6
ASA score		
1	72	45.0
2	81	50.6
3	7	4.4
Previous ESD		
No	149	93.1
Yes	11	6.9
Clinical stage		
IA	133	83.1
IB	27	16.9
Tumor location		
Esophagus involved	0	0
Esophagojejunal junction involved	7	4.4
Subcardial	153	95.6
Type of esophagojejunostomy		
Extracorporeal	45	28.1
Intracorporeal	115	71.9
Stapler for esophagojejunostomy		
Circular	109	68.1
Linear	51	31.9
Type of jejunoejunostomy		
Extracorporeal	110	68.8
Intracorporeal	50	31.2
Method of jejunoejunostomy		
Hand-sewn	40	25.0
Linear	99	61.9
Circular	21	13.1
Extent of LND		
D1	1	0.6
D1 +	98	61.3
D2 –#10	47	29.4
D2	14	8.8

specimen retrieval during intracorporeal esophagojejunostomy, most mini-laparotomy incisions were made through the umbilicus (*n* = 73) or left abdomen (*n* = 52). Mean BMI of patients undergone extracorporeal was 23.7 (range 19.0–28.9) similar to that of patients undergone intracorporeal anastomosis was 24.2 (range 17.3–33.1, *p* = 0.314). The medians of incision length for extra- and intracorporeal

Fig. 1 Study flow chart

anastomosis were 9 cm (range 2–15 cm) and 3.5 cm (range 2–8 cm), respectively. The mean length of mini-laparotomy for extracorporeal anastomosis was significantly longer than that of intracorporeal anastomosis (3.8 versus 8.6 cm, $p < 0.001$).

Ninety-nine patients (61.9%) underwent D1 + dissection or less, and 14 (8.8%) underwent D2 lymph node dissection including lymph node station number 10. No open conversions were reported, and 12 intraoperative complications were recorded in 10 patients. The intraoperative complications included two splenic vessel injuries, two cases of $> 30\%$ splenic ischemia, two cases of splenic capsular tearing, three cases of esophagojejunostomy insufficiency necessitating a laparoscopic reinforce suture, one transverse colon injury, one jejunojejunostomy-site ischemia, and one subcutaneous emphysema.

Postoperative complications (Table 4)

In total, 33 patients (20.6%) experienced complications within 30 days after surgery, including one (0.6%) postoperative mortality. The complication rate of 20.6% (33 out of 160) in our study was not statistically different from that of 18.2% (12 out of 66) in the historical control ($p = 0.814$). Fifteen patients (9.4%) exhibited grade III or higher complications according to Clavien–Dindo classification, including three reoperations. Eight patients were re-admitted to the hospital within 9–27 days after discharge. The most common complications were pulmonary disease ($n = 6$, 3.8%) intra-abdominal abscess ($n = 5$, 3.1%), wound infection ($n = 5$, 3.1%), and anastomotic leakage ($n = 3$, 1.9%). The complication rates of patients who underwent extracorporeal and intracorporeal anastomosis were 28.9% (13/45) and 19.1% (22/115), respectively ($p = 0.204$). Two of the three reoperations were performed due to adhesions around the jejunojejunostomy at 2 weeks after discharge, and a duodenojejunostomy was conducted in both patients. The other reoperation was a distal esophagectomy for leakage at the

Table 3 Surgical and pathological outcomes

Variable	N = 160	(%)
Operation time (min)	226.7 ± 64.5	
Anastomotic time (min)	50.5 ± 23.6	
Intraoperative complications	10	6.3
Estimated blood loss (mL)	135.5 ± 185.8	
Intraoperative transfusions	2	1.3
Open conversion	0	0
Time to first flatus (days)	3.5 ± 1.0	
Time to soft diet (days)	5.7 ± 3.8	
Hospital stay (days)	9.7 ± 7.1	
Postoperative morbidities		
Present	33	20.6
Clavien–Dindo ≥ 3	15	9.4
Postoperative mortality	1	0.6
Readmission after discharge	8	5.0
Reoperation	3	1.9
Tumor size (mm)	30.3 ± 20.8	
Number of tumors		
Single	145	90.6
Multiple	15	9.4
Proximal margin (mm)	33.5 ± 25.5	
Number of harvested lymph nodes	43.5 ± 14.9	
Pathologic T stage		
T0	1	0.6
T1a	71	44.4
T1b	65	40.6
T2	13	8.1
T3	7	4.4
T4a	3	1.9
Pathologic N stage		
N0	143	89.4
N1	8	5.0
N2	5	3.1
N3a	3	1.9
N3b	1	0.6
AJCC stage (7th)		
IA	121	75.6
IB	20	12.5
IIA	11	6.9
IIB	8	5.0

esophagojejunostomy site, which resulted in mortality. The patient experienced mortality was a 62-year-old male who underwent laparoscopic total gastrectomy with intracorporeal esophagojejunostomy. On postoperative day 2, the patient had high fever accompanied with dyspnea and a chest computed tomography demonstrated postoperative pneumonia and early stage acute respiratory distress syndrome. Then, the patient was transferred to intensive care unit and treated conservatively on the same day. During the

Table 4 Postoperative complications

	Type of complication	Clavien–Dindo < 3	Clavien–Dindo ≥ 3	All
Systemic complications	Pulmonary	4	2	6 (3.8%)
	Urinary	2		2 (1.3%)
	Cardiac			–
	Systemic infection			–
	Subtotal	6	2	8 (5.0%)
Local complications	Wound	3	2	5 (3.1%)
	Ascites		1	1 (0.6%)
	Postoperative ileus	1		1 (0.6%)
	Postoperative adhesion		2	2 (1.3%)
	Abdominal abscess	3	2	5 (3.1%)
	Omental infarction	1		1 (0.6%)
	Pancreatic leakage	2		2 (1.3%)
	Acute pancreatitis	1		1 (0.6%)
	Intra-abdominal bleeding			–
	Anastomotic bleeding	1	1	2 (1.3%)
	Anastomotic stenosis			–
	Anastomotic leakage ^a		3	3 (1.9%)
	Duodenal stump leakage		2	2 (1.3%)
	Subtotal	12	13	25 (15.6%)
	Total	18 (11.2%)	15 (9.4%)	33 (20.6%)

^aOne mortality

recovery in the intensive care unit, the feature and color of drainage tube had changed and esophagojejunostomy site leakage was suspected on postoperative day 19. After confirmation of the esophagojejunostomy site leakage, endoscopy was performed and vacuum treatment was applied. However, endoscopic vacuum treatment was not effective and septic condition was worsened. Right transthoracic distal esophagectomy, cervical diverting esophagostomy, segmental resection of jejunal Roux limb, and feeding jejunostomy was performed on postoperative day 30. However, even after the reoperation, sepsis was more aggravated and resulted in mortality on postoperative day 33.

Discussion

This prospective multi-center study on laparoscopic total gastrectomy recorded a postoperative complication rate of 20.6%, which is similar to the reference value of 18% for open total gastrectomy reported in an Italian randomized prospective study [13]. The complication rate recorded in the present trial was not inferior to that in the previous study according to the predetermined threshold value of 8%. Since we used the same criteria for and types of complications, except for wound complications, as those in the Italian randomized prospective study, we could directly compare our results with those of the Italian trial. Our study recorded a mortality rate of 0.6% which is lower than the in-hospital

mortality rate of 8% (5 of 66 patients) after open total gastrectomy in the Italian study. However, since the historical control had more advanced stages than our study, we cannot exclude a higher risk of complications and mortality in the historical control than in our study.

Postoperative complications after total gastrectomy are generally known to be higher than those after other types of gastrectomy for gastric cancer. The complication rate in this study was much higher than that after laparoscopic distal gastrectomy in the KLASS-01 trial, which evaluated laparoscopic distal subtotal gastrectomy for early gastric cancer [6]. The differences in complication type and incidence between laparoscopic total and distal gastrectomy likely stem from the wider extent of lymph node dissection, especially around the pancreas tail and splenic hilum, and greater difficulties in achieving anastomosis during total gastrectomy. Consequently, these features lead to more infectious complications in the abdomen, such as intra-abdominal abscesses, pancreatic fistula, and anastomotic leakages. For comparison, although the incidence of anastomosis-related complications, such as leakage, bleeding, and stenosis, after laparoscopic distal gastrectomy was 1.6% in the KLASS-01 trial, after laparoscopic total gastrectomy was 3.2% in the current study. The rate of pancreas-related complications, such as pancreatitis or pancreatic leakage, was 0.1% for laparoscopic distal gastrectomy, but 1.9% for laparoscopic total gastrectomy in this trial. Intra-abdominal abscesses were recorded in 0.9% after laparoscopic distal gastrectomy

and in 3.1% after laparoscopic total gastrectomy. Although these results cannot be compared statistically due to different surgical extents and treatment strategies, we deduced that anastomosis poses a greater challenge in laparoscopic total gastrectomy that pancreatic injuries occur more frequently during lymph node dissection along the upper border of the pancreas, and that intra-abdominal abscesses more often develop after laparoscopic total gastrectomy. These findings reflect the greater procedural complexity of laparoscopic total gastrectomy in comparison to laparoscopic distal gastrectomy.

Compared to laparoscopic distal gastrectomy in the KLASS-01 trial, laparoscopic total gastrectomy in the present trial showed an operation time longer by 42.6 min and an estimated blood loss larger by 25.5 mL. The longer operation time and larger volume of estimated blood loss during laparoscopic total gastrectomy would be related to more extended lymph node dissection, including dissection along the splenic vessels, and the more complex reconstruction process. Indeed, six of the 12 intraoperative complications were vascular injuries, especially in splenic vessels. In addition, the other three intraoperative complications were associated with the esophagojejunostomy. Additionally, since we did not include incision length as a criterion for open conversion, skin incision larger than 10 cm was made for some patients underwent extracorporeal anastomosis. Although majority of the esophagojejunal anastomosis was done intracorporeally with a relatively small incision, incision length should be considered as an important factor to evaluate the success of laparoscopic procedure.

Although the results of our study seem to be acceptable, there might be an issue regarding the quality of surgeries and validation of participating surgeons before enrollment in the current multicenter clinical trial. As in previously conducted KLASS trials, the current study applied the same criteria for surgeons and institutions for participation in the study. All 22 surgeons who participated in the current study were qualified in laparoscopic gastrectomy, as well as open conventional approaches, and had overcome the learning curve for laparoscopic gastrectomy. Most had participated in the KLASS-01 and KLASS-02 clinical trials. Therefore, unlike other surgical trials, the bias generated by a lack of experience among surgeons could be minimized.

In this study, we conducted a single-arm prospective study of laparoscopic total gastrectomy to compare its short-term results with those reported for open total gastrectomy in previous studies and to determine its technical feasibility and safety. The results of our study emphasize the technical safety of laparoscopic total gastrectomy when it was performed by experienced hands. However, no randomization was performed in the current study, and only one well-designed randomized study in the past decade was available with which to compare our results. Although our study was

a single-arm prospective study, our results can be used as background data for future randomized clinical trials to evaluate the oncological safety of laparoscopic total gastrectomy for gastric cancer or for other studies comparing surgical techniques other than laparoscopic total gastrectomy. Based on our results, laparoscopic total gastrectomy was found to be technically feasible and could be performed safely. As a result, KLASS-05 trial that compares the short-term and long-term results of laparoscopic proximal gastrectomy to those of laparoscopic total gastrectomy is ongoing. In addition, KLASS-01 trial showed that there was no difference in terms of long-term survival between open subtotal gastrectomy and laparoscopic subtotal gastrectomy for stage I gastric cancer. Our KLASS group has started the KLASS-06 trial which is the phase-III randomized trial comparing between the open and laparoscopic total gastrectomy for advanced gastric cancer.

Conclusions

We have addressed the safety and feasibility of laparoscopic total gastrectomy for proximal stage I gastric cancer. Although we did not directly compare results with a control group by randomization, our results suggest that stage I gastric cancer can be a potential candidate for laparoscopic surgery. Further studies should be conducted to investigate long-term survival and recurrence patterns after laparoscopic total gastrectomy, as they are important elements for assessing the oncological safety of any surgical approach.

Compliance with ethical standards

Conflict of interest All authors declare that they have no conflicts of interest.

Ethical standards Each centre's institutional review board or independent ethics committee approved the study. All procedures followed the guiding principles of the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonization. All patients provided written informed consent.

References

1. Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. *Surg Laparosc Endosc*. 1994;4:146–8.
2. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KLASS Trial). *Ann Surg*. 2010;251:417–20.
3. Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, et al. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I

- gastric cancer: a multicenter phase II trial (JCOG 0703). *Gastric Cancer*. 2010;13:238–44.
4. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. *J Clin Oncol*. 2014;32:627–33.
 5. Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, et al. A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). *World J Surg*. 2015;39:2734–41.
 6. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). *Ann Surg*. 2016;263:28–35.
 7. Jeong GA, Cho GS, Kim HH, Lee HJ, Ryu SW, Song KY. Laparoscopy-assisted total gastrectomy for gastric cancer: a multicenter retrospective analysis. *Surgery*. 2009;146:469–74.
 8. Dulucq JL, Wintringer P, Stabilini C, Solinas L, Perissat J, Mahajna A. Laparoscopic and open gastric resections for malignant lesions: a prospective comparative study. *Surg Endosc*. 2005;19:933–8.
 9. Mochiki E, Toyomasu Y, Ogata K, Andoh H, Ohno T, Aihara R, et al. Laparoscopically assisted total gastrectomy with lymph node dissection for upper and middle gastric cancer. *Surg Endosc*. 2008;22:1997–2002.
 10. Du J, Zheng J, Li Y, Li J, Ji G, Dong G, et al. Laparoscopy-assisted total gastrectomy with extended lymph node resection for advanced gastric cancer—reports of 82 cases. *Hepatogastroenterology*. 2010;57:1589–94.
 11. Haverkamp L, Weijts TJ, van der Sluis PC, van der Tweel I, Ruurda JP, van Hillegeersberg R. Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. *Surg Endosc*. 2013;27:1509–20.
 12. Chen K, Xu XW, Zhang RC, Pan Y, Wu D, Mou YP. Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer. *World J Gastroenterol*. 2013;19:5365–76.
 13. Degiuli M, Sasako M, Ponti A. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. *Br J Surg*. 2010;97:643–9.
 14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–13.
 15. Yoo CH, Sohn BH, Han WK, Pae WK. Long-term results of proximal and total gastrectomy for adenocarcinoma of the upper third of the stomach. *Cancer Res Treat*. 2004;36:50–5.
 16. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg*. 2006;93:559–63.
 17. Kim JH, Park SS, Kim J, Boo YJ, Kim SJ, Mok YJ, et al. Surgical outcomes for gastric cancer in the upper third of the stomach. *World J Surg*. 2006;30:1870–6. (**discussion 7–8**).
 18. Topal B, Leys E, Ectors N, Aerts R, Penninckx F. Determinants of complications and adequacy of surgical resection in laparoscopic versus open total gastrectomy for adenocarcinoma. *Surg Endosc*. 2008;22:980–4.
 19. Gong DJ, Miao CF, Bao Q, Jiang M, Zhang LF, Tong XT, et al. Risk factors for operative morbidity and mortality in gastric cancer patients undergoing total gastrectomy. *World J Gastroenterol*. 2008;14:6560–3.
 20. An JY, Youn HG, Choi MG, Noh JH, Sohn TS, Kim S. The difficult choice between total and proximal gastrectomy in proximal early gastric cancer. *Am J Surg*. 2008;196:587–91.
 21. Kawamura H, Yokota R, Homma S, Kondo Y. Comparison of invasiveness between laparoscopy-assisted total gastrectomy and open total gastrectomy. *World J Surg*. 2009;33:2389–95.
 22. Sakuramoto S, Kikuchi S, Futawatari N, Katada N, Moriya H, Hirai K, et al. Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. *Surg Endosc*. 2009;23:2416–23.
 23. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, et al. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. *J Surg Oncol*. 2009;99:275–80.
 24. Sasada S, Ninomiya M, Nishizaki M, Harano M, Ojima Y, Matsukawa H, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. *Anticancer Res*. 2009;29:3347–51.
 25. Koksoy FN, Gonullu D, Catal O, Kuroglu E. Risk factors for operative mortality and morbidity in gastric cancer undergoing D2-gastrectomy. *Int J Surg*. 2010;8:633–5.
 26. Kim MG, Kim BS, Kim TH, Kim KC, Yook JH. The effects of laparoscopic assisted total gastrectomy on surgical outcomes in the treatment of gastric cancer. *J Korean Surg Soc*. 2011;80:245–50.
 27. Kim KT, Jeong O, Jung MR, Ryu SY, Park YK. Outcomes of abdominal total gastrectomy for type II and III gastroesophageal junction tumors: single center's experience in Korea. *J Gastric Cancer*. 2012;12:36–42.

Affiliations

Woo Jin Hyung¹ · Han-Kwang Yang² · Sang-Uk Han³ · Young-Jun Lee⁴ · Joong-Min Park⁵ · Jin Jo Kim⁶ · Oh Kyung Kwon⁷ · Seong Ho Kong² · Hyoung-Il Kim¹ · Hyuk-Joon Lee² · Wook Kim⁸ · Seung Wan Ryu⁹ · Sung-Ho Jin¹⁰ · Sung Jin Oh¹¹ · Keun Won Ryu¹² · Min-Chan Kim¹³ · Hye-Seong Ahn¹⁴ · Young Kyu Park¹⁵ · Young-Ho Kim¹⁶ · Sun-Hwi Hwang¹⁷ · Jong Won Kim⁵ · Gyu Seok Cho¹⁸

¹ Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea

² Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

³ Department of Surgery, Ajou University School of Medicine, Suwon, South Korea

⁴ Department of Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, South Korea

⁵ Department of Surgery, Chung-Ang University College of Medicine, Seoul, South Korea

⁶ Department of Surgery, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Incheon, South Korea

- ⁷ Department of Surgery, Kyungpook National University Medical Center, Daegu, South Korea
- ⁸ Department of Surgery, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
- ⁹ Department of Surgery, Keimyung University School of Medicine, Daegu, South Korea
- ¹⁰ Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
- ¹¹ Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea
- ¹² Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, South Korea
- ¹³ Department of Surgery, Dong-A University College of Medicine, Busan, South Korea
- ¹⁴ Department of Surgery, Seoul National University Boramae Medical Center, Seoul, South Korea
- ¹⁵ Department of Surgery, Chonnam National University Hwasoon Hospital, Hwasun, South Korea
- ¹⁶ Department of Surgery, Kyung Hee University School of Medicine, Seoul, South Korea
- ¹⁷ Department of Surgery, Pusan National University Yangsan Hospital, Yangsan, South Korea
- ¹⁸ Department of Surgery, Soonchunhyang University College of Medicine, 170-Jomaru-ro, Bucheon-si, Gyeonggi-do, South Korea